GH Research PLC

GHRS

Healthcare|Biotechnology|Ireland

$26.67

-0.74 (-2.72%)

Tangible Book

$4.24

Earnings Power

$4.29

About

GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.

Stock Price

+66.2%(1Y)

Pipeline Summary

9 total trials

Phase 1

Phase 2

Phase 3

Phase 4

Completed: 5Recruiting: 1Terminated: 2NOT_YET_RECRUITING: 1

Active Trials (1)

Pharmacokinetics of GH001 Delivered Via a Proprietary Aerosol Delivery Device in Healthy Subjects

NCT06511947Healthy Volunteers

Phase 1Recruiting

Enrollment: 52 participants

BioScore

5.1/10

Watchlist

Ownership

Data last updated: Jul 13, 2026, 12:46 PM